Tekturna’s Loss May Be Entresto’s Gain As Novartis Hopes For Change In The ATMOSPHERE
This article was originally published in The Pink Sheet Daily
Strength of Novartis’ new heart failure drug Entresto contrasts with yet another failed outcomes study for its old renin inhibitor Tekturna.
You may also be interested in...
Clinicians hail the efficacy data behind the new therapy, but some say reimbursement requirements are too onerous, resulting in slow uptake.
Novartis announced Jan. 13 the elimination of nearly 2,000 positions in its U.S. General Medicines business in the wake of the termination of a key clinical study of Tekturna and in anticipation of the expiration of Diovan’s U.S. patent later this year.
Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan